Angioimmunoblastic T-cell Lymphoma
📧 Sign up to get email alerts when something new happens for Angioimmunoblastic T-cell Lymphoma.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2026-04-23Clinical Trial Update: Efficacy and Safety of Oral Azacitidine Compared to Investigator's Choice Therapy in Patients With Relapsed or Refractory AITL [Phase 3]
Phase 3 trial evaluating oral azacitidine versus investigator's choice therapy in relapsed or refractory angioimmunoblastic T-cell lymphoma,…
-
CLINICAL_TRIALS research · 2026-04-21Clinical Trial Update: AZD3470 as Monotherapy or in Combination With Anticancer Agent(s) in Participants With Haematologic Malignancies. [Phase 1, Phase 2]
This document describes a Phase 1/Phase 2 clinical trial evaluating AZD3470 as a monotherapy or in combination with other anticancer agents …
-
CLINICAL_TRIALS research · 2026-04-13Clinical Trial Update: A Vaccine (VSV-hIFNβ-NIS) With or Without Cyclophosphamide and Combinations of Ipilimumab, Nivolumab, and Cemiplimab in Treating Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia or Lymphoma [Phase 1]
A Phase 1 clinical trial evaluating the VSV-hIFNβ-NIS vaccine with or without cyclophosphamide and in combination with ipilimumab, nivolumab…
-
CLINICAL_TRIALS research · 2026-04-13Clinical Trial Update: Anti-ICOS Monoclonal Antibody MEDI-570 in Treating Patients With Relapsed or Refractory Peripheral T-cell Lymphoma Follicular Variant or Angioimmunoblastic T-cell Lymphoma [Phase 1]
This clinical trial update discusses MEDI-570, an anti-ICOS monoclonal antibody, in relapsed or refractory peripheral T-cell lymphoma follic…
-
CLINICAL_TRIALS trial_result · 2026-04-08Clinical Trial Update: Soquelitinib vs Standard of Care in Participants With Relapsed/Refractory Peripheral T-cell Lymphoma Not Otherwise Specified, Follicular Helper T-cell Lymphomas, or Systemic Anaplastic Large-cell Lymphoma [Phase 3]
Soquelitinib is being studied in a Phase 3 trial versus standard of care for relapsed/refractory peripheral T-cell lymphomas, including PTCL…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2026-04-02Clinical Trial Update: Testing the Addition of Duvelisib or CC-486 to the Usual Treatment for Peripheral T-Cell Lymphoma [Phase 2]
A Phase 2 trial evaluating adding duvelisib or CC-486 to standard therapy for several peripheral T-cell lymphomas has been suspended.
-
CLINICAL_TRIALS withdrawal · 2026-04-01Clinical Trial Update: Tazemetostat Plus CHOP in 1L T-cell Lymphoma [Phase 2]
A Phase 2 trial evaluating tazemetostat in combination with CHOP for first-line T-cell lymphomas has been withdrawn.
-
CLINICAL_TRIALS research · 2026-03-31Clinical Trial Update: Azacitidine and Abatacept in Relapsed or Refractory T-Cell Lymphoma [Phase 1]
Phase 1 trial evaluating azacitidine with abatacept for relapsed or refractory T-cell lymphomas is currently recruiting.
-
CLINICAL_TRIALS trial_result · 2026-03-16Clinical Trial Update: Phase I/II Study Evaluating AUTO4 in Patients With T Cell Receptor Beta Constant (TRBC)1 Positive T Cell Lymphoma [Phase 1, Phase 2]
Clinical trial update for AUTO4 in TRBC1-positive T-cell lymphomas shows Phase 1/2 results with the study terminated and results posted.
-
CLINICAL_TRIALS research · 2026-02-20Clinical Trial Update: A Phase I Trial Anti-CC Chemokine Receptor 4 Chimeric Antigen Receptor T Cells (CCR4 CAR T Cells) for CCR4 Expressing T-cell Malignancies Including Peripheral T-cell Non-Hodgkin Lymphoma (PTCL) and Cutaneous T-cell Non-Hodgkin Lymphoma (CTCL) [Phase 1]
A Phase 1 clinical trial is evaluating CCR4-directed CAR T cells in CCR4-expressing mature T-cell malignancies, including peripheral T-cell …
-
CLINICAL_TRIALS research · 2026-02-10Clinical Trial Update: A Study of ARV-393 in Relapsed/Refractory Non-Hodgkin Lymphoma. [Phase 1]
A Phase 1 trial of ARV-393 is evaluating safety and dosing for Relapsed/Refractory mature B-cell Non-Hodgkin lymphoma and Relapsed/Refractor…
-
CLINICAL_TRIALS trial_result · 2026-01-09Clinical Trial Update: Study of Pembrolizumab (MK-3475) in Combination With Romidepsin [Phase 1, Phase 2]
A Phase 1/2 clinical trial evaluating pembrolizumab in combination with romidepsin for recurrent or refractory T-cell lymphomas; the study i…
-
CLINICAL_TRIALS research · 2025-12-30Clinical Trial Update: Cholecalciferol in Improving Survival in Patients With Newly Diagnosed Cancer With Vitamin D Insufficiency [NA]
A Mayo Clinic-sponsored clinical trial evaluates cholecalciferol (vitamin D3) for improving survival in patients with newly diagnosed cancer…
-
CLINICAL_TRIALS research · 2025-12-12Clinical Trial Update: Ruxolitinib in Combination With CHOP Chemotherapy for the Treatment of Untreated Nodal T-Follicular Helper Cell Lymphomas [Phase 1]
Phase 1 trial evaluating ruxolitinib in combination with CHOP chemotherapy as first-line therapy for untreated nodal Follicular Helper T-cel…
-
CLINICAL_TRIALS research · 2025-12-02Clinical Trial Update: Ro Plus CHOEP as First Line Treatment Before HSCT in Young Patients With Nodal Peripheral T-cell Lymphomas [Phase 1, Phase 2]
A Phase 1/2 clinical trial (NCT02223208) evaluates Ro plus CHOEP as first-line therapy before hematopoietic stem cell transplantation in you…
-
CLINICAL_TRIALS trial_result · 2025-11-21Clinical Trial Update: A Phase II Study of Single Agent Brentuximab Vedotin in Relapsed/Refractory CD30 Low (<10%) Mature T Cell Lymphoma (TCL) [Phase 2]
This Phase II study evaluates single-agent Brentuximab Vedotin in relapsed/refractory CD30-low mature T-cell lymphomas; the trial has comple…
-
CLINICAL_TRIALS research · 2025-09-22Clinical Trial Update: Phase 1 Trial of ST-001 nanoFenretinide in Relapsed/Refractory T-cell Non-Hodgkin Lymphoma [Phase 1]
Phase 1 trial of ST-001 nanoFenretinide for relapsed/refractory T-cell non-Hodgkin lymphoma is currently recruiting, targeting multiple T-ce…
-
CLINICAL_TRIALS research · 2025-09-11Clinical Trial Update: Tislelizumab , Cyclophosphamide, Mitoxantrone Liposomes, Chidamide, and Prednisone in the Treatment of New Diagnosed AITL [Phase 2]
A Phase 2 trial is investigating a five-drug combination (tislelizumab, cyclophosphamide, liposomal mitoxantrone, chidamide, and prednisone)…
-
CLINICAL_TRIALS research · 2025-07-10Clinical Trial Update: Tislelizumab , Cyclophosphamide, Mitoxantrone Liposomes, Chidamide, and Prednisone in the Treatment of R/R AITL [Phase 2]
Phase 2 clinical trial evaluating a five-drug regimen (tislelizumab, cyclophosphamide, mitoxantrone liposomes, chidamide, and prednisone) fo…
-
CLINICAL_TRIALS research · 2025-07-01Clinical Trial Update: Clinical Study of CEP+Dasatinib + Azacytidine in First-line Treatment of. Angioimmunoblastoma Foresight [Phase 4]
This Phase 4 clinical trial, sponsored by Zhengzhou University, is evaluating a CEP+dasatinib+azacitidine regimen as first-line therapy for …
-
CLINICAL_TRIALS trial_result · 2025-06-06Clinical Trial Update: Anti-CD7 CAR-T Cell Therapy for Relapse and Refractory CD7 Positive T Cell Malignancies [Phase 1]
Phase 1 trial evaluating anti-CD7 CAR-T cell therapy for relapsed/refractory CD7-positive T-cell malignancies has completed, assessing safet…
-
CLINICAL_TRIALS research · 2025-04-29Clinical Trial Update: Dose-Escalation and Dose-Expansion Study to Evaluate the Safety and Tolerability of Anti-CD7 Allogeneic CAR T-Cells (WU-CART-007) in Patients With CD7+ Hematologic Malignancies [Phase 1]
This clinical trial update describes a Phase 1 dose-escalation and dose-expansion study of anti-CD7 allogeneic CAR T-cells (WU-CART-007) in …
-
CLINICAL_TRIALS trial_result · 2025-03-28Clinical Trial Update: Daratumumab Plus Gemcitabine, Dexamethasone, Cisplatin in pt R/R CD38+ PTCL-NOS, AITL and TFH [Phase 2]
Phase 2 trial of daratumumab with gemcitabine, dexamethasone, and cisplatin in relapsed/refractory CD38+ peripheral T-cell lymphoma subtypes…
-
CLINICAL_TRIALS research · 2024-12-09Clinical Trial Update: Testing Whether High Dose Chemotherapy and Infusion of the Patients' Own Stem Cells Improves Survival in Patients With Peripheral T-cell Lymphoma Who Achieved a Complete Response at the End of the Initial Chemotherapy [Phase 3]
Phase 3 trial to evaluate whether high-dose chemotherapy followed by autologous stem cell transplantation improves survival in peripheral T-…
-
CLINICAL_TRIALS trial_result · 2024-08-27Clinical Trial Update: Pembrolizumab and Pralatrexate in Treating Patients With Relapsed or Refractory Peripheral T-Cell Lymphomas [Phase 1, Phase 2]
This clinical trial update covers a Phase 1/2 study of pembrolizumab plus pralatrexate in relapsed or refractory peripheral T-cell lymphomas…